SCHEDULE: Venrock Entities File Schedule 13G for X4 Pharmaceuticals

Several Venrock-affiliated entities and individuals have jointly filed a Schedule 13G, reporting beneficial ownership of 5.6% of X4 Pharmaceuticals, Inc. common stock.

Summary

• A group of reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have jointly filed a Schedule 13G.
• This filing indicates their beneficial ownership of 5,555,047 shares of X4 Pharmaceuticals, Inc. common stock.
• This ownership represents 5.6% of the class of securities outstanding as of July 31, 2026.
• The reporting persons are organized in Delaware, with Nimish Shah and Bong Koh being U.S. citizens.
• The filing confirms that these securities were not acquired or are not held for the purpose of or with the effect of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, with no new financial or strategic information that would significantly impact the stock price.

Positives

• The filing clarifies the ownership stake of significant Venrock-affiliated entities in X4 Pharmaceuticals, Inc.
• The joint filing agreement and powers of attorney demonstrate a coordinated approach to regulatory compliance.

Negatives

• No new financial performance data or strategic updates are provided in this filing.

Risks

• The filing does not contain any specific risk factors related to the company's operations or market position.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is Venrock assuming, any of the undersigneds responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors and investment firms reporting significant ownership stakes. This filing confirms Venrock's continued investment in X4 Pharmaceuticals, Inc. within the broader healthcare and biotechnology investment landscape.

Stakeholder Impact

• Shareholders are informed of the beneficial ownership of a significant investment group, providing transparency on major holders.

Next Steps

• The Powers of Attorney remain in effect until the earliest of: (a) the undersigned is no longer required to file any form or document with respect to the undersigneds holdings and transactions in securities, (b) revocation by the undersigned in a signed writing, or (c) the attorney-in-fact is no longer employed by Venrock.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, X4 Pharmaceuticals, Venrock, Securities Exchange Act, Investment Management, Healthcare Capital